Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching
Significant differences in clinical response, loss of response, and time-to-event analysis between originator and biosimilar adalimumab in HS underscore the need for consistent treatment and robust monitoring to optimize management.
Authors
- James P. Pham (ORCID: https://orcid.org/0000-0002-9263-3889)
- John W. Frew (ORCID: https://orcid.org/0000-0001-5042-3632)
- Cindy Kok (ORCID: https://orcid.org/0000-0003-3086-7097)
- K Burrell
- Marra Aghajani (ORCID: https://orcid.org/0000-0002-8088-4509)
- Tara Sholji
Institutions
- UNSW Sydney (AU)
Publication Details
- Journal
- JAAD International
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1016/j.jdin.2025.05.023
- Citations
- 1
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.00